Caladrius Biosciences, Inc. (CLBS): Product News News

CLBS – Reports results from the predetermined interim analysis in The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase 2 clinical trial of 110 patients to evaluate the safety and efficacy of the Company’s CLBS03 as a treatment for recent-onset type 1 diabetes.

Key Facts Surrounding This News Item

  • CLBS had a POWR Rating of B (Buy) coming into today.
  • CLBS was 18.68% above its 10-Day Moving Average coming into today.
  • CLBS was 30.91% above its 20-Day Moving Average coming into today.
  • CLBS was 38.78% above its 50-Day Moving Average coming into today.
  • CLBS was 54.29% above its 100-Day Moving Average coming into today.
  • CLBS was 45.35% above its 200-Day Moving Average coming into today.
  • CLBS had returned +63.25% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Caladrius Biosciences, Inc. (CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. View our full CLBS ticker page with ratings, news, and more.

Try Premium Today!

Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

CLBS at a Glance

CLBS Current POWR Rating™
Overall POWR Rating™
CLBS Current Price $5.95 8.46%
More CLBS Ratings, Data, and News

CLBS Price Reaction

The day of this event (Mar. 8, 2018)
CLBS Closing Price$5.37 6.28%
CLBS Volume165,800
156.83% from avg
Leading up to this event
CLBS 1-mo return42.89%
After this event
CLBS 1-day return3.24%
CLBS 3-day return0.35%
CLBS 5-day return0.87%

CLBS Price Chart

More Caladrius Biosciences, Inc. (CLBS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLBS News
Page generated in 1.1716 seconds.